Human Apyrase to Disrupt Cancer Therapy

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$196,745.00
Award Year:
2008
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA130192-01A2
Award Id:
88864
Agency Tracking Number:
CA130192
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
APT THERAPEUTICS, INC., 893 NORTH WARSON ROAD, SAINT LOUIS, MO, 63141
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
192266141
Principal Investigator:
RIDONG CHEN
(314) 608-6932
RCHEN@NIDUSCENTER.COM
Business Contact:
() -
rchen@niduscenter.com
Research Institute:
n/a
Abstract
DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for inhibition of cancer metastasis. The enzyme strongly inhibits platelet activation and aggregation without increasing bleeding risk. Using a protein informatics app roach, we have successfully engineered an optimized human apyrase, APT102. With the Phase I grant support, we will determine whether APT102, alone or in combination with aspirin, is effective in inhibiting experimental spontaneous metastasis in mice. PUBLI C HEALTH RELEVANCE:Human apyrase represents a highly promising therapy for cancer treatment. We will determine whether the targeted apyrase, alone or in combination with aspirin, is effective in inhibiting experimental metastasis in mice.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government